{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:40:48Z","timestamp":1787002848467,"version":"build-2736575974"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Clear cell renal cell carcinoma (ccRCC) remains a major clinical challenge due to its high metastatic potential and limited treatment options. Here, we identified\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    as a critical tumor suppressor, whose downregulation drives ccRCC aggressiveness. Through integrated molecular analyses, we demonstrated that\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    deficiency promoted proliferation, epithelial-to-mesenchymal transition, and metastatic dissemination in both in vitro and in vivo models. Mechanistically,\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    knockdown activated mTOR signaling, leading to aberrant HIF2\u03b1 stabilization, a well-established oncogenic driver in ccRCC. Upstream of this cascade,\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    loss was associated with increased focal adhesion kinase (FAK) activation, providing a context-specific link between membrane signaling and mTOR-HIF2\u03b1 pathway activation. Pharmacological inhibition of mTOR suppresses HIF2\u03b1 activity and targeting either pathway partially rescues the hyperproliferative and pro-metastatic phenotype of\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    -deficient cells. Proteomic analysis further revealed that\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    loss reprograms lipid metabolism, particularly by increasing fatty acid synthesis and lipid droplet (LD) formation. We identify\n                    <jats:italic>PLIN2<\/jats:italic>\n                    , a HIF2\u03b1-regulated gene, as a key mediator of LD stability in\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    -knockdown cells. By sequestering lipids into LDs,\n                    <jats:italic>PLIN2<\/jats:italic>\n                    protects against ferroptosis, an iron-dependent form of cell death triggered by lipid peroxidation. Notably,\n                    <jats:italic>PLIN2<\/jats:italic>\n                    knockdown increases ferroptotic sensitivity, revealing LD biogenesis as a major survival mechanism in\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    -deficient ccRCC. Together, these findings establish a\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    \u2013mTOR\u2013HIF2\u03b1\u2013\n                    <jats:italic>PLIN2<\/jats:italic>\n                    axis that underlines both metastatic behavior and ferroptosis evasion. Clinically, this suggests that combining ferroptosis inducers with mTOR or HIF2\u03b1 inhibitors\u2014and potentially targeting\n                    <jats:italic>PLIN2<\/jats:italic>\n                    \u2014could provide a multifaceted therapeutic strategy against advanced ccRCC. By elucidating the tumor-suppressive role of\n                    <jats:italic>PCDHGC3<\/jats:italic>\n                    , this study expands our understanding of clustered\n                    <jats:italic>PCDH<\/jats:italic>\n                    biology and offers novel insights for ccRCC management.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08643-y","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:23:05Z","timestamp":1774549385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PCDHGC3 silencing promotes clear cell renal cell carcinoma metastasis via mTOR\/HIF2\u03b1 activation, lipid metabolism rewiring, and ferroptosis evasion"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3058-7231","authenticated-orcid":false,"given":"Luc\u00eda","family":"Celada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Cubiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-9408","authenticated-orcid":false,"given":"Jaime","family":"San-Juan-Guardado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Su\u00e1rez-Priede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"G\u00f3mez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Da Silva Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9831-0810","authenticated-orcid":false,"given":"Helena","family":"Herrada-Manch\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Alejandro","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1112-1583","authenticated-orcid":false,"given":"Mar\u00eda-Dolores","family":"Chiara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"8643_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Prim. 2017;3:17009.","journal-title":"Nat Rev Dis Prim"},{"key":"8643_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.727778","volume":"11","author":"X Qi","year":"2021","unstructured":"Qi X, Li Q, Che X, Wang Q, Wu G. The uniqueness of clear cell renal cell carcinoma: summary of the process and abnormality of glucose metabolism and lipid metabolism in ccRCC. Front Oncol. 2021;11:727778.","journal-title":"Front Oncol"},{"key":"8643_CR3","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3390\/cancers11091227","volume":"11","author":"JC Angulo","year":"2019","unstructured":"Angulo JC, Shapiro O. The changing therapeutic landscape of metastatic renal cancer. Cancers. 2019;11:1227.","journal-title":"Cancers"},{"key":"8643_CR4","doi-asserted-by":"publisher","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","volume":"13","author":"WG Kaelin","year":"2007","unstructured":"Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007;13:680s\u2013684s.","journal-title":"Clin Cancer Res"},{"key":"8643_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/07357907.2011.584782","volume":"29","author":"M Hager","year":"2011","unstructured":"Hager M, Haufe H, Lusuardi L, Schmeller N, Kolbitsch C. PTEN, pAKT, and pmTOR expression and subcellular distribution in primary renal cell carcinomas and their metastases. Cancer Invest. 2011;29:427\u201338.","journal-title":"Cancer Invest"},{"key":"8643_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/cells13010034","volume":"13","author":"L Meng","year":"2023","unstructured":"Meng L, Collier KA, Wang P, Li Z, Monk P, Mortazavi A, et al. EmergIng immunotherapy approaches for advanced clear cell renal cell carcinoma. Cells. 2023;13:34.","journal-title":"Cells"},{"key":"8643_CR7","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/ijc.34756","volume":"154","author":"NR Wilson","year":"2024","unstructured":"Wilson NR, Acikgoz Y, Hasanov E. Advances in non-clear cell renal cell carcinoma management: from heterogeneous biology to treatment options. Int J Cancer. 2024;154:947\u201361.","journal-title":"Int J Cancer"},{"key":"8643_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/cancers16030601","volume":"16","author":"CB Nguyen","year":"2024","unstructured":"Nguyen CB, Oh E, Bahar P, Vaishampayan UN, Else T, Alva AS. Novel approaches with HIF-2\u03b1 targeted therapies in metastatic renal cell carcinoma. Cancers. 2024;16:601.","journal-title":"Cancers"},{"key":"8643_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251317846","volume":"17","author":"X Wu","year":"2025","unstructured":"Wu X, Lazris D, Wong R, Tykodi SS. Belzutifan for the treatment of renal cell carcinoma. Ther Adv Med Oncol. 2025;17:17588359251317846.","journal-title":"Ther Adv Med Oncol"},{"key":"8643_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc3647","volume":"14","author":"F van Roy","year":"2014","unstructured":"van Roy F. Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer. 2014;14:121\u201334.","journal-title":"Nat Rev Cancer"},{"key":"8643_CR11","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1073\/pnas.1918167117","volume":"117","author":"T-Y Na","year":"2020","unstructured":"Na T-Y, Schecterson L, Mendonsa AM, Gumbiner BM. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci USA. 2020;117:5931\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8643_CR12","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00018-017-2572-3","volume":"74","author":"SL Peek","year":"2017","unstructured":"Peek SL, Mah KM, Weiner JA. Regulation of neural circuit formation by protocadherins. Cell Mol Life Sci. 2017;74:4133\u201357.","journal-title":"Cell Mol Life Sci"},{"key":"8643_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.gde.2020.05.041","volume":"65","author":"E Flaherty","year":"2020","unstructured":"Flaherty E, Maniatis T. The role of clustered protocadherins in neurodevelopment and neuropsychiatric diseases. Curr Opin Genet Dev. 2020;65:144\u201350.","journal-title":"Curr Opin Genet Dev"},{"key":"8643_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-cellbio-100616-060701","volume":"34","author":"G Mountoufaris","year":"2018","unstructured":"Mountoufaris G, Canzio D, Nwakeze CL, Chen WV, Maniatis T. Writing, reading, and translating the clustered protocadherin cell surface recognition code for neural circuit assembly. Annu Rev Cell Dev Biol. 2018;34:471\u201393.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"8643_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/19336918.2014.1000069","volume":"9","author":"AB Keeler","year":"2015","unstructured":"Keeler AB, Molumby MJ, Weiner JA. Protocadherins branch out: multiple roles in dendrite development. Cell Adh Migr. 2015;9:214\u201326.","journal-title":"Cell Adh Migr"},{"key":"8643_CR16","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/onc.2011.609","volume":"31","author":"AR Dallosso","year":"2012","unstructured":"Dallosso AR, \u00d8ster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene. 2012;31:4409\u201319.","journal-title":"Oncogene"},{"key":"8643_CR17","doi-asserted-by":"publisher","first-page":"e1000745","DOI":"10.1371\/journal.pgen.1000745","volume":"5","author":"AR Dallosso","year":"2009","unstructured":"Dallosso AR, Hancock AL, Szemes M, Moorwood K, Chilukamarri L, Tsai H-H, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms\u2019 tumor. PLoS Genet. 2009;5:e1000745.","journal-title":"PLoS Genet"},{"key":"8643_CR18","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1210\/jc.2018-01471","volume":"104","author":"C Bernardo-Casti\u00f1eira","year":"2019","unstructured":"Bernardo-Casti\u00f1eira C, Vald\u00e9s N, Celada L, Martinez ASJ, S\u00e1enz-de-Santa-Mar\u00eda I, Bay\u00f3n GF, et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas\/paragangliomas associated with SDHB mutations. J Clin Endocrinol Metab. 2019;104:5673\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"8643_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/path.6291","volume":"263","author":"T Cubiella","year":"2024","unstructured":"Cubiella T, Celada L, San-Juan-Guardado J, Rodr\u00edguez-Aguilar R, Su\u00e1rez-Priede \u00c1, Poch M, et al. PCDHGC3 hypermethylation as a potential biomarker of intestinal neuroendocrine carcinomas. J Pathol. 2024;263:418\u201328.","journal-title":"J Pathol"},{"key":"8643_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-019-0695-0","volume":"11","author":"AF Vega-Benedetti","year":"2019","unstructured":"Vega-Benedetti AF, Loi E, Moi L, Blois S, Fadda A, Antonelli M, et al. Clustered protocadherins methylation alterations in cancer. Clin Epigenet. 2019;11:100.","journal-title":"Clin Epigenet"},{"key":"8643_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1471-4159.2011.07587.x","volume":"120","author":"MA Lobas","year":"2012","unstructured":"Lobas MA, Helsper L, Vernon CG, Schreiner D, Zhang Y, Holtzman MJ, et al. Molecular heterogeneity in the choroid plexus epithelium: the 22-member \u03b3-protocadherin family is differentially expressed, apically localized, and implicated in CSF regulation. J Neurochem. 2012;120:913\u201327.","journal-title":"J Neurochem"},{"key":"8643_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2021.112357","volume":"128","author":"H Herrada-Manch\u00f3n","year":"2021","unstructured":"Herrada-Manch\u00f3n H, Celada L, Rodr\u00edguez-Gonz\u00e1lez D, Alejandro Fern\u00e1ndez M, Aguilar E, Chiara M-D. Three-dimensional bioprinted cancer models: a powerful platform for investigating tunneling nanotube-like cell structures in complex microenvironments. Mater Sci Eng C Mater Biol Appl. 2021;128:112357.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"8643_CR23","volume":"5","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5:100625.","journal-title":"Innovation"},{"key":"8643_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13072-015-0014-8","volume":"8","author":"A D\u00edez-Villanueva","year":"2015","unstructured":"D\u00edez-Villanueva A, Mallona I, Peinado MA. Wanderer, an interactive viewer to explore DNA methylation and gene expression data in human cancer. Epigenetcs Chromatin. 2015;8:22.","journal-title":"Epigenetcs Chromatin"},{"key":"8643_CR25","doi-asserted-by":"publisher","first-page":"8391","DOI":"10.3390\/ijms24098391","volume":"24","author":"SC Badoiu","year":"2023","unstructured":"Badoiu SC, Greabu M, Miricescu D, Stanescu-Spinu I-I, Ilinca R, Balan DG, et al. PI3K\/AKT\/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL\/HIF axis. Int J Mol Sci. 2023;24:8391.","journal-title":"Int J Mol Sci"},{"key":"8643_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/cancers8060057","volume":"8","author":"Q Xu","year":"2016","unstructured":"Xu Q, Krause M, Samoylenko A, Vainio S. Wnt signaling in renal cell carcinoma. Cancers. 2016;8:57.","journal-title":"Cancers"},{"key":"8643_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/genes16010006","volume":"16","author":"G Roviello","year":"2024","unstructured":"Roviello G, De Gennaro I, Vascotto I, Venturi G, D\u2019Angelo A, Winchler C, et al. Hypoxia-inducible factor in renal cell carcinoma: from molecular insights to targeted therapies. Genes. 2024;16:6.","journal-title":"Genes"},{"key":"8643_CR28","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1158\/1541-7786.MCR-11-0302","volume":"9","author":"B Kucejova","year":"2011","unstructured":"Kucejova B, Pe\u00f1a-Llopis S, Yamasaki T, Sivanand S, Tran TAT, Alexander S, et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res. 2011;9:1255\u201365.","journal-title":"Mol Cancer Res"},{"key":"8643_CR29","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0895-822","volume":"1","author":"O Iliopoulos","year":"1995","unstructured":"Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995;1:822\u20136.","journal-title":"Nat Med"},{"key":"8643_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","volume":"5","author":"B Qiu","year":"2015","unstructured":"Qiu B, Ackerman D, Sanchez DJ, Li B, Ochocki JD, Grazioli A, et al. HIF2\u03b1-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma. Cancer Discov. 2015;5:652\u201367.","journal-title":"Cancer Discov"},{"key":"8643_CR31","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1126\/science.aal3231","volume":"356","author":"WV Chen","year":"2017","unstructured":"Chen WV, Nwakeze CL, Denny CA, O\u2019Keeffe S, Rieger MA, Mountoufaris G, et al. Pcdh\u03b1c2 is required for axonal tiling and assembly of serotonergic circuitries in mice. Science. 2017;356:406\u201311.","journal-title":"Science"},{"key":"8643_CR32","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1523\/JNEUROSCI.0729-22.2022","volume":"43","author":"DM Steffen","year":"2023","unstructured":"Steffen DM, Hanes CM, Mah KM, Vali\u00f1o Ramos P, Bosch PJ, Hinz DC, et al. A Unique role for protocadherin \u03b3C3 in promoting dendrite arborization through an axin1-dependent mechanism. J Neurosci. 2023;43:918\u201335.","journal-title":"J Neurosci"},{"key":"8643_CR33","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.neuron.2023.03.012","volume":"111","author":"S Meltzer","year":"2023","unstructured":"Meltzer S, Boulanger KC, Chirila AM, Osei-Asante E, DeLisle M, Zhang Q, et al. \u03b3-Protocadherins control synapse formation and peripheral branching of touch sensory neurons. Neuron. 2023;111:1776\u201394.e10.","journal-title":"Neuron"},{"key":"8643_CR34","doi-asserted-by":"publisher","first-page":"e1008554","DOI":"10.1371\/journal.pgen.1008554","volume":"15","author":"AM Garrett","year":"2019","unstructured":"Garrett AM, Bosch PJ, Steffen DM, Fuller LC, Marcucci CG, Koch AA, et al. CRISPR\/Cas9 interrogation of the mouse Pcdhg gene cluster reveals a crucial isoform-specific role for Pcdhgc4. PLoS Genet. 2019;15:e1008554.","journal-title":"PLoS Genet"},{"key":"8643_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313596120","volume":"121","author":"WRM Leon","year":"2024","unstructured":"Leon WRM, Steffen DM, Dale-Huang FR, Rakela B, Breevoort A, Romero-Rodriguez R, et al. The clustered gamma protocadherin Pcdh\u03b3C4 isoform regulates cortical interneuron programmed cell death in the mouse cortex. Proc Natl Acad Sci USA. 2024;121:e2313596120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8643_CR36","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1074\/jbc.M807417200","volume":"284","author":"J Chen","year":"2009","unstructured":"Chen J, Lu Y, Meng S, Han MH, Lin C, Wang X. \u03b1- and \u03b3-protocadherins negatively regulate PYK2. J Biol Chem. 2009;284:2880\u201390.","journal-title":"J Biol Chem"},{"key":"8643_CR37","doi-asserted-by":"publisher","first-page":"20674","DOI":"10.1074\/jbc.M115.642306","volume":"290","author":"AB Keeler","year":"2015","unstructured":"Keeler AB, Schreiner D, Weiner JA. Protein kinase C phosphorylation of a \u03b3-protocadherin C-terminal lipid binding domain regulates focal adhesion kinase inhibition and dendrite arborization. J Biol Chem. 2015;290:20674\u201386.","journal-title":"J Biol Chem"},{"key":"8643_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep31665","volume":"6","author":"KM Mah","year":"2016","unstructured":"Mah KM, Houston DW, Weiner JA. The \u03b3-Protocadherin-C3 isoform inhibits canonical Wnt signalling by binding to and stabilizing Axin1 at the membrane. Sci Rep. 2016;6:31665.","journal-title":"Sci Rep"},{"key":"8643_CR39","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s11864-023-01106-y","volume":"24","author":"R Ahmed","year":"2023","unstructured":"Ahmed R, Ornstein MC. Targeting HIF-2 alpha in renal cell carcinoma. Curr Treat Options Oncol. 2023;24:1183\u201398.","journal-title":"Curr Treat Options Oncol"},{"key":"8643_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/14737140.2017.1273774","volume":"17","author":"JL Gonz\u00e1lez-Larriba","year":"2017","unstructured":"Gonz\u00e1lez-Larriba JL, Maroto P, Dur\u00e1n I, Lambea J, Flores L, Castellano D, et al. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges. Expert Rev Anticancer Ther. 2017;17:217\u201326.","journal-title":"Expert Rev Anticancer Ther"},{"key":"8643_CR41","doi-asserted-by":"publisher","first-page":"34495","DOI":"10.1074\/jbc.C800170200","volume":"283","author":"A Toschi","year":"2008","unstructured":"Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J Biol Chem. 2008;283:34495\u20139.","journal-title":"J Biol Chem"},{"key":"8643_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.neuron.2012.01.028","volume":"74","author":"AM Garrett","year":"2012","unstructured":"Garrett AM, Schreiner D, Lobas MA, Weiner JA. \u03b3-protocadherins control cortical dendrite arborization by regulating the activity of a FAK\/PKC\/MARCKS signaling pathway. Neuron. 2012;74:269\u201376.","journal-title":"Neuron"},{"key":"8643_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01482-4","volume":"22","author":"L Qiu","year":"2024","unstructured":"Qiu L, Sun Y, Ning H, Chen G, Zhao W, Gao Y. The scaffold protein AXIN1: gene ontology, signal network, and physiological function. Cell Commun Signal. 2024;22:77.","journal-title":"Cell Commun Signal"},{"key":"8643_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","volume":"20","author":"SK Tan","year":"2023","unstructured":"Tan SK, Hougen HY, Merchan JR, Gonzalgo ML, Welford SM. Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. Nat Rev Urol. 2023;20:48\u201360.","journal-title":"Nat Rev Urol"},{"key":"8643_CR45","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","volume":"34","author":"M Martin-Perez","year":"2022","unstructured":"Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, Benitah SA. The role of lipids in cancer progression and metastasis. Cell Metab. 2022;34:1675\u201399.","journal-title":"Cell Metab"},{"key":"8643_CR46","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Ladanyi","year":"2018","unstructured":"Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37:2285\u2013301.","journal-title":"Oncogene"},{"key":"8643_CR47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13046-019-1049-7","volume":"38","author":"J Pan","year":"2019","unstructured":"Pan J, Fan Z, Wang Z, Dai Q, Xiang Z, Yuan F, et al. CD36 mediates palmitate acid-induced metastasis of gastric cancer via AKT\/GSK-3\u03b2\/\u03b2-catenin pathway. J Exp Clin Cancer Res. 2019;38:52.","journal-title":"J Exp Clin Cancer Res"},{"key":"8643_CR48","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.7150\/thno.34024","volume":"9","author":"M Jiang","year":"2019","unstructured":"Jiang M, Wu N, Xu B, Chu Y, Li X, Su S, et al. Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis. Theranostics. 2019;9:5359\u201373.","journal-title":"Theranostics"},{"key":"8643_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14262-3","volume":"11","author":"C Corbet","year":"2020","unstructured":"Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander Linden C, et al. TGF\u03b22-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11:454.","journal-title":"Nat Commun"},{"key":"8643_CR50","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s13046-019-1391-9","volume":"38","author":"J Wen","year":"2019","unstructured":"Wen J, Min X, Shen M, Hua Q, Han Y, Zhao L, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exp Clin Cancer Res. 2019;38:401.","journal-title":"J Exp Clin Cancer Res"},{"key":"8643_CR51","first-page":"4280","volume":"12","author":"W Guo","year":"2019","unstructured":"Guo W, Abudumijiti H, Xu L, Hasim A. CD147 promotes cervical cancer migration and invasion by up-regulating fatty acid synthase expression. Int J Clin Exp Pathol. 2019;12:4280\u20138.","journal-title":"Int J Clin Exp Pathol"},{"key":"8643_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113434","volume":"196","author":"E Jonasch","year":"2024","unstructured":"Jonasch E, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, et al. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort. Eur J Cancer. 2024;196:113434.","journal-title":"Eur J Cancer"},{"key":"8643_CR53","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.2217\/fon-2023-0283","volume":"19","author":"TK Choueiri","year":"2023","unstructured":"Choueiri TK, Powles T, Voss MH, Plimack ER, Gurney H, Song Y, et al. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma. Future Oncol. 2023;19:2631\u201340.","journal-title":"Future Oncol"},{"key":"8643_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/23247096241231641","volume":"12","author":"KH Chan","year":"2024","unstructured":"Chan KH, Li N, Lador R, Amsbaugh M, Gonzalez A, Cen P. Belzutifan, HIF-2\u03b1 inhibitor, and clear cell renal cell carcinoma with somatic Von-Hippel-Lindau loss-of-function mutation. J Investig Med High Impact Case Rep. 2024;12:23247096241231641.","journal-title":"J Investig Med High Impact Case Rep"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08643-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08643-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T07:03:50Z","timestamp":1778051030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08643-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8643"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08643-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}